뇌졸중 치료제 파이프라인 분석 - 2026년(Q2 인사이트 및 임상시험)

Pharmaceutical and biotechnology companies are actively advancing novel thrombolytics, neuroprotective agents, anti-inflammatory therapies, regenerative medicines, and combination approaches to address the significant unmet clinical needs in acute stroke management and long-term recovery.

Stroke remains one of the leading causes of death and long-term disability worldwide, with ischemic stroke representing the primary focus of pipeline development. Although thrombolysis and mechanical thrombectomy have significantly improved clinical outcomes, many patients remain ineligible for current interventions or continue to experience permanent neurological impairment. Drug pipeline analysis provides comprehensive insights into investigational therapies, clinical development stages, mechanisms of action, sponsor activities, regulatory trends, competitive positioning, and commercialization opportunities that are shaping the future stroke treatment landscape.

Market Drivers

Growing Global Stroke Burden

• The increasing incidence of stroke resulting from aging populations, hypertension, diabetes, obesity, atrial fibrillation, and other cardiovascular risk factors continues to accelerate demand for innovative therapeutic options. The substantial healthcare and economic burden associated with stroke is encouraging sustained investment in drug discovery and clinical development.

Expansion of Next-Generation Reperfusion Therapies

• Growing clinical interest in improving reperfusion outcomes has accelerated development of next-generation thrombolytic agents that offer simplified administration, faster treatment, and broader patient eligibility. Recent regulatory advances have further strengthened investment in this therapeutic area.

Increasing Focus on Neuroprotection

• Pharmaceutical companies are expanding research into neuroprotective therapies designed to preserve neuronal tissue during ischemic injury and improve long-term functional recovery. These therapies represent one of the most promising areas of pipeline innovation.

Advances in Imaging-Guided Treatment

• Improved neuroimaging technologies are enabling more precise patient selection and extending treatment windows, encouraging sponsors to develop therapies that complement imaging-guided stroke management strategies.

Market Restraints

High Clinical Failure Rates

• Neuroprotective drug development has historically experienced high attrition rates because of complex stroke biology, heterogeneous patient populations, and difficulties in demonstrating consistent clinical benefit.

Complex Clinical Development

• Stroke drug development requires rapid patient enrollment, standardized imaging protocols, large multicenter studies, and long-term neurological outcome assessment, making clinical trials expensive and operationally demanding.

Regulatory Challenges

• Regulatory agencies require robust evidence demonstrating meaningful improvements in functional recovery while maintaining acceptable safety profiles, particularly regarding bleeding risk associated with reperfusion therapies.

Pipeline and Technology Insights

• The global stroke drug pipeline can be segmented by development phase, stroke type, drug type, treatment type, mechanism of action, and geography.
• By development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and filed/under regulatory review candidates. Phase II and Phase III programs represent the largest share of active development as sponsors advance promising therapies toward commercialization.
• By stroke type, pipeline activity covers ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and other cerebrovascular disorders. Ischemic stroke dominates development because it represents the majority of stroke cases and offers the greatest opportunity for therapeutic innovation.
• By drug type, the pipeline includes thrombolytics, antiplatelets, anticoagulants, neuroprotective agents, anti-inflammatory therapies, regenerative therapies, and other investigational drug classes. Thrombolytics remain the most active development category, while neuroprotective and regenerative therapies continue to expand as sponsors pursue complementary treatment approaches.
• By treatment type, pipeline assets include intravenous medications, endovascular therapies, and surgical procedures, including mechanical thrombectomy and carotid endarterectomy. Drug developers increasingly seek therapies that complement existing interventional procedures and improve functional outcomes.
• Technological innovation continues to support pipeline advancement through artificial intelligence-assisted imaging, biomarker-guided patient selection, precision medicine, adaptive clinical trial designs, and digital health platforms that improve trial efficiency and treatment optimization.

Pipeline Trends

• The global stroke drug pipeline continues to evolve toward targeted and combination therapeutic strategies.

Key trends include:

• Expansion of next-generation thrombolytic development.
• Increasing investment in neuroprotective therapies.
• Growing development of combination therapies with thrombectomy.
• Broader use of imaging-guided patient selection.
• Expansion of regenerative medicine and neurological recovery programs.
• Increasing adoption of adaptive clinical trial designs.
• Greater focus on extending treatment eligibility windows.

Regional Insights

• North America remains the leading region for stroke drug pipeline development because of advanced clinical research infrastructure, strong regulatory support, extensive academic collaboration, and substantial pharmaceutical investment. The United States continues to lead commercialization and late-stage clinical development.
• Europe maintains a strong position through multinational clinical research networks, established stroke care systems, and active participation in global drug development programs. Imaging-guided treatment strategies continue to drive innovation across the region.
• Asia-Pacific is expected to emerge as one of the fastest-growing regions for stroke drug development owing to increasing stroke prevalence, expanding clinical trial capabilities, improving healthcare infrastructure, and growing pharmaceutical investment across China, Japan, South Korea, India, and Australia.
• Latin America and the Middle East & Africa are gradually strengthening their participation in multinational clinical research through healthcare modernization, expanding stroke treatment capacity, and increasing collaboration with international pharmaceutical companies.

Competitive Landscape

• The global stroke drug pipeline includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, and emerging biotechnology developers.
• Leading organizations continue investing in next-generation thrombolytics, neuroprotective agents, regenerative medicine, anti-inflammatory therapies, precision medicine, and combination treatment strategies. Strategic licensing agreements, collaborative research partnerships, mergers and acquisitions, and regulatory acceleration programs remain central to competitive growth. Companies including Genentech, Boehringer Ingelheim, Roche, Novartis, Bayer, Johnson & Johnson, Daiichi Sankyo, and Sanofi are actively strengthening their stroke development portfolios.

Future Outlook

• The future of the stroke drug pipeline will be shaped by continued advances in precision neurology, artificial intelligence, regenerative medicine, imaging-guided treatment, and personalized therapeutics. Expansion of neuroprotective strategies, improved understanding of stroke pathophysiology, and broader integration of digital health technologies are expected to accelerate development of innovative therapies.
• Increasing adoption of adaptive trial designs, biomarker-guided development, and combination treatment approaches will improve development efficiency while creating new commercial opportunities through 2035.

Conclusion

• The global Stroke Drug Pipeline Analysis highlights a rapidly expanding development landscape supported by growing neurological research investment, innovation in thrombolytic therapies, advances in neuroprotection, and increasing emphasis on improving long-term functional recovery. Although challenges related to clinical complexity, regulatory requirements, and historical failure rates remain, continued advances in precision medicine, imaging technologies, and combination therapeutic strategies are expected to accelerate innovation and strengthen future commercialization opportunities.

Key Benefits of this Report

• Comprehensive analysis of the global stroke drug pipeline across all stages of development.
• Detailed evaluation of investigational therapies, mechanisms of action, and pipeline maturity.
• Competitive assessment of sponsor activities, strategic collaborations, and licensing trends.
• Insights into regulatory developments, emerging technologies, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, contract research organizations, healthcare providers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

• Pipeline benchmarking, portfolio optimization, competitive intelligence, licensing and partnership evaluation, clinical development planning, investment analysis, regulatory strategy development, commercialization planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global stroke drug pipeline by development phase, stroke type, drug type, treatment type, and geography
• Evaluation of pipeline assets, clinical development progress, mechanisms of action, sponsor landscape, regulatory pathways, and commercialization potential
• Assessment of strategic collaborations, licensing agreements, mergers and acquisitions, competitive positioning, and emerging therapeutic innovations
• Analysis of thrombolytics, neuroprotective therapies, regenerative medicine, antiplatelets, anticoagulants, combination therapies, and future pipeline opportunities through 2035.

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Research Methodology
• 1.2. Research Scope
  • 1.2.1. Analysis by Company
  • 1.2.2. Analysis by Development Phase
  • 1.2.3. Analysis by Intervention Type
  • 1.2.4. Analysis by Clinical Trial Status
  • 1.2.5. Analysis by Geography
• 1.3. Data Sources and Validation
• 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

• 2.1. Introduction
• 2.2. Disease Classification
• 2.3. Causes and Risk Factors
• 2.4. Symptoms and Clinical Manifestations
• 2.5. Diagnosis
• 2.6. Current Treatment Landscape
• 2.7. Epidemiology and Disease Burden
• 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

• 3.1. Clinical-Stage Pipeline Overview
• 3.2. Pipeline Distribution by Development Phase
• 3.3. Leading Companies by Clinical Trial Activity
• 3.4. Leading Investigational Drugs and Interventions
• 3.5. Geographic Clinical Trial Landscape
• 3.6. Key Pipeline Trends and Findings

4. STROKE PIPELINE DYNAMICS

• 4.1. Drivers
• 4.2. Restraints
• 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

• 5.1. PIPELINE ANALYSIS BY COMPANY
  • 5.1.1. Genentech
  • 5.1.2. Boehringer Ingelheim
  • 5.1.3. F. Hoffmann-La Roche
  • 5.1.4. Novartis
• 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
  • 5.2.1. Early Phase I
  • 5.2.2. Phase I
  • 5.2.3. Phase I/II
  • 5.2.4. Phase II
  • 5.2.5. Phase II/III
  • 5.2.6. Phase III
• 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
  • 5.3.1. Drug
  • 5.3.2. Biological
  • 5.3.3. Genetic
• 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
  • 5.4.1. Ischemic Stroke
  • 5.4.2. Hemorrhagic Stroke
  • 5.4.3. Post-Stroke Recovery / Secondary Prevention
• 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
  • 5.5.1. Not Yet Recruiting
  • 5.5.2. Recruiting
  • 5.5.3. Active, Not Recruiting
  • 5.5.4. Completed
  • 5.5.5. Terminated / Withdrawn / Suspended
• 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia-Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa
• 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
  • 5.7.1. Clinical Trials by Patient Enrollment
  • 5.7.2. Clinical Trials by Study Design
  • 5.7.3. Patient Age Eligibility
  • 5.7.4. Patient Sex Eligibility
• 5.8. SPONSOR AND COLLABORATION ANALYSIS
  • 5.8.1. Leading Commercial Sponsors
  • 5.8.2. Leading Academic and Research Sponsors
  • 5.8.3. Leading Collaborating Organizations
  • 5.8.4. Sponsor-Collaborator Analysis
• 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
  • 5.9.1. Recently Initiated Clinical Trials
  • 5.9.2. Newly Recruiting Clinical Trials
  • 5.9.3. Recently Completed Clinical Trials
  • 5.9.4. Late-Stage Trials Approaching Primary Completion
  • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

• 6.1. Genentech
• 6.2. Boehringer Ingelheim
• 6.3. F. Hoffmann-La Roche
• 6.4. Novartis

7. LIST OF TABLES

8. LIST OF FIGURES